Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith T Flaherty

Showing results (41-50 of 418) with videos related to

Pageof 42
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2011
New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advancesKeith T Flaherty, David E Fisher
Journal of Skin Cancer|December 17, 2011
BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and ResistanceRyan J Sullivan, Keith T Flaherty
Journal of the National Comprehensive Cancer Network : JNCCN|April 30, 2009
Where are we with adjuvant therapy of stage III and IV melanoma in 2009?Leslie A Fecher, Keith T Flaherty
Clinical Advances in Hematology & Oncology : H&O|August 4, 2007
Targeted therapy for metastatic melanomaRavi K Amaravadi, Keith T Flaherty
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
CCR drug updates: sorafenib and sunitinib in renal cell carcinomaMark N Stein, Keith T Flaherty
Nature Cancer|February 5, 2022
Tracking early response to immunotherapyGenevieve M Boland, Keith T Flaherty
Pigment Cell & Melanoma Research|January 11, 2014
Cyclin-dependent kinases as therapeutic targets in melanomaDavid M Miller, Keith T Flaherty
Future Oncology (London, England)|August 12, 2009
Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatmentKeiran S M Smalley, Keith T Flaherty
Cancer Biology & Therapy|February 1, 2007
Is ERK activation a good biomarker for estradiol and tamoxifen effects?Keiran S M Smalley, Keith T Flaherty
Melanoma Management|September 8, 2018
Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanomaPhilip Eliades, Keith T Flaherty, Hensin Tsao
Pageof 42

Showing results (41-50 of 418) with videos related to

Sort By:
Pageof 42
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2011
New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advancesKeith T Flaherty, David E Fisher
Journal of Skin Cancer|December 17, 2011
BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and ResistanceRyan J Sullivan, Keith T Flaherty
Journal of the National Comprehensive Cancer Network : JNCCN|April 30, 2009
Where are we with adjuvant therapy of stage III and IV melanoma in 2009?Leslie A Fecher, Keith T Flaherty
Clinical Advances in Hematology & Oncology : H&O|August 4, 2007
Targeted therapy for metastatic melanomaRavi K Amaravadi, Keith T Flaherty
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
CCR drug updates: sorafenib and sunitinib in renal cell carcinomaMark N Stein, Keith T Flaherty
Nature Cancer|February 5, 2022
Tracking early response to immunotherapyGenevieve M Boland, Keith T Flaherty
Pigment Cell & Melanoma Research|January 11, 2014
Cyclin-dependent kinases as therapeutic targets in melanomaDavid M Miller, Keith T Flaherty
Future Oncology (London, England)|August 12, 2009
Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatmentKeiran S M Smalley, Keith T Flaherty
Cancer Biology & Therapy|February 1, 2007
Is ERK activation a good biomarker for estradiol and tamoxifen effects?Keiran S M Smalley, Keith T Flaherty
Melanoma Management|September 8, 2018
Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanomaPhilip Eliades, Keith T Flaherty, Hensin Tsao
Pageof 42